EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group ( COG ) AHOD1331 trial

Dana L Casey iD, Lindsay A Renfro, Yue Wu, Kathleen McCarten, Qinglin Pei, Sarah A Milgrom, Jennifer A Belsky, Steve Cho, Frank G Keller, Angela Punnett, David C Hodgson, Bradford S Hoppe iD und 2 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70625 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Dana L Casey und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Hodgkin Disease, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: St. Baldrick's Foundation, Imaging and Radation Oncology Core Rhode Island, Quality Assurance Review Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Outcomes for high‐risk paediatric classic Hodgkin lymphoma (cHL) improved with the addition of brentuximab vedotin (Bv) to doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (AVEPC) chemotherapy. We evaluated the prognostic implications of distant extra‐nodal sites contributing to stage IV disease. On AHOD1331 (NCT02166463), patients aged 2–21 years with high‐risk cHL (stage IIB with bulk/IIIB/IVA/IVB) were randomized to 5 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide (ABVE‐PC) versus Bv‐AVEPC. Patients with stage IV disease, determined by protocol‐defined and centrally reviewed Positron Emission Tomography ‐ Computed Tomography (PET‐CT), were identified. Baseline characteristics and progression‐free survival (PFS) were compared by pattern of stage IV involvement (lung, bone, bone marrow, multiple sites and others). A total of 340 patients (median age 15 years) with stage IV disease were included. Of these patients, 173 (51%) received ABVE‐PC and 167 (49%) Bv‐AVEPC. PFS was highest with lung‐only involvement (4‐year PFS 88.6%) and lowest with bone marrow‐only involvement (4‐year PFS 71.9%). Compared to ABVE‐PC, Bv‐AVEPC improved PFS among all stage IV patients (hazard ratio [HR] 0.53, 90% confidence interval (CI) 0.33–0.85) and in the lung‐only and bone‐only subgroups. However, no PFS benefit was observed in those with bone marrow‐only involvement. Among paediatric patients with stage IV cHL, Bv‐AVEPC improved PFS across most patterns of stage IV disease, except in those with bone marrow involvement. These results will guide efforts to improve outcomes among children with stage IV cHL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseAntineoplastic Combined Chemotherapy ProtocolsHumansChildAdolescentChild, PreschoolFemaleNeoplasm StagingMaleYoung AdultBleomycinCyclophosphamidePrednisoneEtoposideDoxorubicinVincristineTreatment OutcomeBrentuximab Vedotin

Stichwörter der Autor:innen

classic Hodgkin lymphomapaediatric oncologystage IV disease

Substanzen

BleomycinCyclophosphamidePrednisoneEtoposideDoxorubicinVincristineBrentuximab Vedotin

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Division of Biostatistics, University of Southern California, Los Angeles, California, USA.
  • Children's Oncology Group, Monrovia, California, USA.
  • Department of Biostatistics, Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, Florida, USA.
  • Pediatric Radiology, Imaging and Radiation Oncology Core Rhode Island, Lincoln, Rhode Island, USA.
  • Department of Radiation Oncology, University of Colorado, Aurora, Colorado, USA.

ORCID-Profile: Dana L Casey, Bradford S Hoppe

Förderung

  • St. Baldrick's Foundation
  • Imaging and Radation Oncology Core Rhode Island
  • Quality Assurance Review Center
  • Seattle Genetics Inc. (now Pfizer Inc.)
  • NCI NIH HHS
  • NIH HHS
  • Leukemia and Lymphoma Society (now Blood Cancer United)
  • National Institutes of Health

Zitieren

APA

Casey, D. L., Renfro, L. A., Wu, Y., McCarten, K., Pei, Q., Milgrom, S. A., Belsky, J. A., Cho, S., Keller, F. G., Punnett, A., Hodgson, D. C., Hoppe, B. S., Kelly, K. M., & Castellino, S. M. (2026). Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group ( COG ) AHOD1331 trial. British Journal of Haematology. https://doi.org/10.1111/bjh.70625

Vancouver

Casey DL, Renfro LA, Wu Y, McCarten K, Pei Q, Milgrom SA, et al. Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group ( COG ) AHOD1331 trial. British Journal of Haematology. 2026. doi:10.1111/bjh.70625

BibTeX
@article{Casey2026,
  author = {Casey, Dana L and Renfro, Lindsay A and Wu, Yue and McCarten, Kathleen and Pei, Qinglin and Milgrom, Sarah A and Belsky, Jennifer A and Cho, Steve and Keller, Frank G and Punnett, Angela and Hodgson, David C and Hoppe, Bradford S and Kelly, Kara M and Castellino, Sharon M},
  title = {Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group ( COG ) AHOD1331 trial},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70625}
}
Kostenlos starten →